BridgeBio Oncology Therapeutics financials
$3.92+2.89%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$60.2M | -$46.2M | -$43.4M | -$49.2M |
| Net income | -$56.5M | -$42.1M | -$38.8M | -$44.8M |
| Net margin | — | — | — | — |
| Diluted EPS | $-705.20 | $-526.11 | $-0.48 | $-1.03 |
| EBITDA | -$60.0M | -$46.0M | -$43.0M | -$49.0M |
| Operating cash flow | -$44.4M | -$35.9M | -$42.2M | -$70.6M |
| Free cash flow | -$44.4M | -$35.9M | -$42.3M | -$71.2M |
| Diluted shares | 0.1M | 0.1M | 80.6M | 43.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $54.1M | $52.7M | $373.7M | $408.7M |
| Short-term investments | $171.6M | $199.6M | $51.8M | $59.5M |
| Total debt | $0.00 | $716.0K | $0.00 | $691.0K |
| Total assets | $376.7M | $417.6M | $448.4M | $484.8M |
| Total liabilities | $53.6M | $45.4M | $37.3M | $38.1M |
| Shareholders' equity | $323.1M | $372.3M | $411.1M | $446.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology